KromaTiD Receives $2.0 Million of Growth Capital Investment from BroadOak Capital Partners

29 Apr, 2021

KromaTiD Receives $2.0 Million of Growth Capital Investment from BroadOak Capital Partners
Photo by alevision.co on Unsplash

BroadOak Capital Partners has invested in KromaTiD.
– KromaTiD’s sales and operations are rapidly accelerating, driven by growing market adoption of their products and services, such as the recently launched dGH In-Site™ and dGH SCREEN™ products for gene editing and gene therapy applications.
– This capital will be used to accelerate commercialization, support ongoing product development, and to increase capacity to meet growing demand.
– KromaTiD’s directional Genomic Hybridization™, or dGH™, today provides the genomic structural context necessary to optimize gene editing strategies for research and clinical purposes, such as therapeutic gene editing based on CRISPR technologies, requiring measurements that can only be made with a single cell, genome-wide analysis provided by dGH™.

Biotechnology Developer Platform Genetics Medical North America
Crunchbase icon

Content report

The following text will be sent to our editors: